Hyperglycaemia is considered an on-target effect of PI3K inhibitors, which is relevant to the crucial role of the PI3K pathway in insulin signalling and glucose homeostasis (Juric et al. 2018). The gene discussed is PIK3CG; the disease is Hyperglycemia.